search
Back to results

New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders) (ABCD)

Primary Purpose

Alzheimer Disease, Behavioral Disorders, Cognitive Impairment

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Ecological Environmental therapy
Sponsored by
Universita di Verona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer Disease focused on measuring Neurological Disorders, Non Pharmacological Treatment, Ecological Therapy

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Person with Alzheimer's disease.

Exclusion Criteria:

  • Bedridden patients.

Sites / Locations

  • Mons. Mazzali Foundation

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Experimental group (TR)

Control group (CTRL)

Arm Description

A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.

A group of 80 patients with AD will be treated with the standard therapy.

Outcomes

Primary Outcome Measures

Evaluations of Behavioral Disorders
Through the use of Neuropsychiatric Inventory (NPI), the investigators assessed the frequency and the severity of the behavioral disorders. The total scale range of the NPI is 0-144, and higher values represent worse outcome.
Evaluation of Cognitive Status (Score 0-30)
Through the use of Mini Mental State Examination (MMSE) the investigators estimated the severity and progression of cognitive impairment. MMSE is a questionnaire that examines cognitive functions including registration, attention, calculation, recall, language, ability to follow simple commands and orientation. The scale range of the MMSE tests is 0-30, and higher values represent a better outcome.

Secondary Outcome Measures

Body Composition (Kilograms of Fat Free Mass)
Body mass and skin-fold measurements were measured three times a day by the same experienced operator. The average value of the three measurements was calculated. Kilograms of fat free mass was estimated using a validated equation.
Systolic Blood Pressure (mmHg)
Systolic blood pressure were measured with standard auscultatory and mercury sphygmomanometer technique.
Diastolic Blood Pressure (mmHg)
Diastolic blood pressure were measured with standard auscultatory and mercury sphygmomanometer technique.
Blood Glucose (mg/dl)
A fasted venous blood sample will be analyzed for glucose blood levels by standard techniques.
Blood Cholesterol HDL (mg/dl)
A fasted venous blood sample was analyzed for high-density lipoprotein blood levels by standard techniques.
Blood Cholesterol LDL (mg/dl)
A fasted venous blood sample was analyzed for low-density lipoprotein blood levels by standard techniques.
Daily Energy Expenditure (Kcal/Day)
Daily energy expenditure was measured with an Actiheart device (CamNtech, Cambridge, UK) allowing heart rate and acceleration data to be simultaneously recorded for 24 h/day for 7 consecutive days.
Evaluation of Activity of Daily Life
Independence and level of activities of daily life (ADL) were evaluated with the Barthel index. Levels of ADL was measured by observing each resident's daily activities (eating, bathing, grooming, dressing, transfers from bed to chair, mobility on level planes, stairs, and getting on/off the toilet). The total score of the Barthel index is 0-100, and higher values represent a better outcome.
Salivary Cortisol (Nmol/l)
Levels of cortisol was measured via saliva samples using plain Sarstedt Salivette collection devices (Nümbrecht, Germany). Samples will be collected at 6.30 AM, 11.30 AM, and 6.30 PM. Immediately after collecting the saliva samples, were centrifuged for 2 min at 1,000 rpm. Purified saliva was stored in a freezer at -20 °C, and subsequently analyzed. Cortisol levels was determined by a time-resolved immunoassay with fluorometric detection.
Number of Medications
Number of Patients Treated With Quetiapine
Number of Patients Treated With Citalopram
Number of Patients Treated With Donepezil
Number of Patients Treated With Memantine
Number of Patients Treated With Ticlopidin

Full Information

First Posted
May 28, 2015
Last Updated
September 14, 2018
Sponsor
Universita di Verona
Collaborators
Mons. Mazzali Foundation (Mantua, Italy)
search

1. Study Identification

Unique Protocol Identification Number
NCT02462291
Brief Title
New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Acronym
ABCD
Official Title
Effectiveness of Environmental Therapy in Patients With Alzheimer's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
June 2015 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universita di Verona
Collaborators
Mons. Mazzali Foundation (Mantua, Italy)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Alzheimer's disease (AD) is the most frequent form of dementia, causing high level of disability with elevated social costs. Alternative solutions to the standard pharmacological therapies have been studied in order to reduce the use of medications that frequently generates side effects and worsen patients' quality of life. A recent alternative treatment for AD is the Environmental Ecological Therapy (EET) that, with the use of therapeutic gardens, seems to reduce behavioral disorders (BD). However, the effectiveness of this approach is still mater of debate. Therefore, the aim of this trial will be to analyze the effects of EET, in people with severe AD.
Detailed Description
Since Homo sapiens evolved in a natural environment, an intrinsic physiologic and psychological positive reaction to nature has been developed. Accordingly, emerging literature highlights the positive effect of therapeutic gardens, as environmental ecological therapy (EET) on the reduction of behavioral disorders (BD) and the preservation of cognitive functions in patients with Alzheimer's disease (AD). Despite these promising preliminary studies, limited data are available on the effectiveness of EET in individuals with advanced AD. Therefore, the aim of the current trial will be to evaluate the effectiveness of EET on AD symptoms in patients with advanced AD. Participants with advanced AD will be selected from among residents of the Alzheimer's care units of the Mons. Mazzali Foundation (Mantua, Italy). Selected participants will be randomly assigned to a treatment group (TR), or to a control group (CTRL). Participants assigned to TR group will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months. Individuals assigned to the CTRL group will be treated with a standard therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease, Behavioral Disorders, Cognitive Impairment
Keywords
Neurological Disorders, Non Pharmacological Treatment, Ecological Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
163 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental group (TR)
Arm Type
Experimental
Arm Description
A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
Arm Title
Control group (CTRL)
Arm Type
No Intervention
Arm Description
A group of 80 patients with AD will be treated with the standard therapy.
Intervention Type
Other
Intervention Name(s)
Ecological Environmental therapy
Intervention Description
The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
Primary Outcome Measure Information:
Title
Evaluations of Behavioral Disorders
Description
Through the use of Neuropsychiatric Inventory (NPI), the investigators assessed the frequency and the severity of the behavioral disorders. The total scale range of the NPI is 0-144, and higher values represent worse outcome.
Time Frame
PRE and POST 6 months of treatment
Title
Evaluation of Cognitive Status (Score 0-30)
Description
Through the use of Mini Mental State Examination (MMSE) the investigators estimated the severity and progression of cognitive impairment. MMSE is a questionnaire that examines cognitive functions including registration, attention, calculation, recall, language, ability to follow simple commands and orientation. The scale range of the MMSE tests is 0-30, and higher values represent a better outcome.
Time Frame
PRE and POST 6 months of treatment
Secondary Outcome Measure Information:
Title
Body Composition (Kilograms of Fat Free Mass)
Description
Body mass and skin-fold measurements were measured three times a day by the same experienced operator. The average value of the three measurements was calculated. Kilograms of fat free mass was estimated using a validated equation.
Time Frame
PRE and POST 6 months of treatment
Title
Systolic Blood Pressure (mmHg)
Description
Systolic blood pressure were measured with standard auscultatory and mercury sphygmomanometer technique.
Time Frame
PRE and POST 6 months of treatment
Title
Diastolic Blood Pressure (mmHg)
Description
Diastolic blood pressure were measured with standard auscultatory and mercury sphygmomanometer technique.
Time Frame
PRE and POST 6 months of treatment
Title
Blood Glucose (mg/dl)
Description
A fasted venous blood sample will be analyzed for glucose blood levels by standard techniques.
Time Frame
PRE and POST 6 months of treatment
Title
Blood Cholesterol HDL (mg/dl)
Description
A fasted venous blood sample was analyzed for high-density lipoprotein blood levels by standard techniques.
Time Frame
PRE and POST 6 months of treatment
Title
Blood Cholesterol LDL (mg/dl)
Description
A fasted venous blood sample was analyzed for low-density lipoprotein blood levels by standard techniques.
Time Frame
PRE and POST 6 months of treatment
Title
Daily Energy Expenditure (Kcal/Day)
Description
Daily energy expenditure was measured with an Actiheart device (CamNtech, Cambridge, UK) allowing heart rate and acceleration data to be simultaneously recorded for 24 h/day for 7 consecutive days.
Time Frame
PRE and POST 6 months of treatment
Title
Evaluation of Activity of Daily Life
Description
Independence and level of activities of daily life (ADL) were evaluated with the Barthel index. Levels of ADL was measured by observing each resident's daily activities (eating, bathing, grooming, dressing, transfers from bed to chair, mobility on level planes, stairs, and getting on/off the toilet). The total score of the Barthel index is 0-100, and higher values represent a better outcome.
Time Frame
PRE and POST 6 months of treatment
Title
Salivary Cortisol (Nmol/l)
Description
Levels of cortisol was measured via saliva samples using plain Sarstedt Salivette collection devices (Nümbrecht, Germany). Samples will be collected at 6.30 AM, 11.30 AM, and 6.30 PM. Immediately after collecting the saliva samples, were centrifuged for 2 min at 1,000 rpm. Purified saliva was stored in a freezer at -20 °C, and subsequently analyzed. Cortisol levels was determined by a time-resolved immunoassay with fluorometric detection.
Time Frame
PRE and POST 6 months of treatment
Title
Number of Medications
Time Frame
PRE and POST 6 months of treatment
Title
Number of Patients Treated With Quetiapine
Time Frame
PRE and POST 6 months of treatment
Title
Number of Patients Treated With Citalopram
Time Frame
PRE and POST 6 months of treatment
Title
Number of Patients Treated With Donepezil
Time Frame
PRE and POST 6 months of treatment
Title
Number of Patients Treated With Memantine
Time Frame
PRE and POST 6 months of treatment
Title
Number of Patients Treated With Ticlopidin
Time Frame
PRE and POST 6 months of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Person with Alzheimer's disease. Exclusion Criteria: Bedridden patients.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Massimo Venturelli, Ph.D.
Organizational Affiliation
Universita di Verona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Federico Schena, MD; Ph.D.
Organizational Affiliation
Universita di Verona
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Nicola Smania, MD
Organizational Affiliation
Universita di Verona
Official's Role
Study Chair
Facility Information:
Facility Name
Mons. Mazzali Foundation
City
Mantua Italy
State/Province
Mantua
ZIP/Postal Code
46100
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
19893184
Citation
Calkins MP. Evidence-based long term care design. NeuroRehabilitation. 2009;25(3):145-54. doi: 10.3233/NRE-2009-0512.
Results Reference
background
PubMed Identifier
19531775
Citation
Friedrich MJ. Therapeutic environmental design aims to help patients with Alzheimer disease. JAMA. 2009 Jun 17;301(23):2430. doi: 10.1001/jama.2009.809. No abstract available.
Results Reference
background
PubMed Identifier
22707959
Citation
Detweiler MB, Sharma T, Detweiler JG, Murphy PF, Lane S, Carman J, Chudhary AS, Halling MH, Kim KY. What is the evidence to support the use of therapeutic gardens for the elderly? Psychiatry Investig. 2012 Jun;9(2):100-10. doi: 10.4306/pi.2012.9.2.100. Epub 2012 May 22.
Results Reference
background
PubMed Identifier
18276956
Citation
Detweiler MB, Murphy PF, Myers LC, Kim KY. Does a wander garden influence inappropriate behaviors in dementia residents? Am J Alzheimers Dis Other Demen. 2008 Feb-Mar;23(1):31-45. doi: 10.1177/1533317507309799.
Results Reference
background
PubMed Identifier
20150654
Citation
Smith R, Mathews RM, Gresham M. Pre- and postoccupancy evaluation of new dementia care cottages. Am J Alzheimers Dis Other Demen. 2010 May;25(3):265-75. doi: 10.1177/1533317509357735. Epub 2010 Feb 11.
Results Reference
background
PubMed Identifier
19366885
Citation
Detweiler MB, Murphy PF, Kim KY, Myers LC, Ashai A. Scheduled medications and falls in dementia patients utilizing a wander garden. Am J Alzheimers Dis Other Demen. 2009 Aug-Sep;24(4):322-32. doi: 10.1177/1533317509334036. Epub 2009 Apr 14.
Results Reference
background
PubMed Identifier
15359562
Citation
Heath Y. Evaluating the effect of therapeutic gardens. Am J Alzheimers Dis Other Demen. 2004 Jul-Aug;19(4):239-42. doi: 10.1177/153331750401900410.
Results Reference
background
PubMed Identifier
3942940
Citation
Rodenburg M. Special facilities for patients with Alzheimer's disease. CMAJ. 1986 Feb 15;134(4):315-6. No abstract available.
Results Reference
background
PubMed Identifier
23207487
Citation
Rivasseau Jonveaux T, Batt M, Fescharek R, Benetos A, Trognon A, Bah Chuzeville S, Pop A, Jacob C, Yzoard M, Demarche L, Soulon L, Malerba G, Bouvel B. Healing gardens and cognitive behavioral units in the management of Alzheimer's disease patients: the Nancy experience. J Alzheimers Dis. 2013;34(1):325-38. doi: 10.3233/JAD-121657.
Results Reference
background
PubMed Identifier
24128125
Citation
Gonzalez MT, Kirkevold M. Benefits of sensory garden and horticultural activities in dementia care: a modified scoping review. J Clin Nurs. 2014 Oct;23(19-20):2698-715. doi: 10.1111/jocn.12388. Epub 2013 Oct 15.
Results Reference
background
PubMed Identifier
19893188
Citation
York SL. Residential design and outdoor area accessibility. NeuroRehabilitation. 2009;25(3):201-8. doi: 10.3233/NRE-2009-0516.
Results Reference
background
PubMed Identifier
24219216
Citation
Venturelli M, Scarsini R, Muti E, Salvagno GL, Schena F. Sundowning syndrome and hypothalamic-pituitary-adrenal axis dysregulation in individuals with Alzheimer's disease: is there an association? J Am Geriatr Soc. 2013 Nov;61(11):2055-6. doi: 10.1111/jgs.12491. No abstract available.
Results Reference
background
PubMed Identifier
22984089
Citation
Venturelli M, Magalini A, Scarsini R, Schena F. From Alzheimer's disease retrogenesis: a new care strategy for patients with advanced dementia. Am J Alzheimers Dis Other Demen. 2012 Nov;27(7):483-9. doi: 10.1177/1533317512459794. Epub 2012 Sep 13.
Results Reference
background
PubMed Identifier
21852281
Citation
Venturelli M, Scarsini R, Schena F. Six-month walking program changes cognitive and ADL performance in patients with Alzheimer. Am J Alzheimers Dis Other Demen. 2011 Aug;26(5):381-8. doi: 10.1177/1533317511418956. Epub 2011 Aug 17.
Results Reference
background
PubMed Identifier
20209421
Citation
Venturelli M, Lanza M, Muti E, Schena F. Positive effects of physical training in activity of daily living-dependent older adults. Exp Aging Res. 2010 Apr;36(2):190-205. doi: 10.1080/03610731003613771.
Results Reference
background

Learn more about this trial

New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)

We'll reach out to this number within 24 hrs